Between 4Q16 and 4Q17, Wall Street analysts expect Pfizer’s (PFE) revenue to rise ~0.8% to $13.72 billion from $13.63 billion. However, analysts expect it to fall ~0.5% to $52.6 billion in 2017 from $52.8 billion in 2016. They expect Pfizer to see EPS (earnings per share) of $0.56 in 4Q17 and $2.59 in 2017.
The above chart shows analysts’ recommendations for Pfizer stock. Its price has risen ~11.5% over the last 12 months. Analysts’ estimates suggest that the stock could return ~5.7% over the next 12 months. Analysts have given Pfizer a 12-month target price of $38.29 per share, while the stock stood at $36.22 per share on December 29, 2017.
On December 29, 2017, of the 24 analysts tracking Pfizer, 13 recommended “buy,” nine recommended “hold,” and recommended “sell.” The consensus rating for Pfizer stands at 2.5, which represents a moderate “buy” for value investors. Changes in analysts’ estimates and recommendations are due to stock price changes, company performance in recent quarters, and recent developments that may have short-term and long-term effects on that performance. The First Trust NASDAQ Pharmaceuticals ETF (FTXH) holds 7.7% of its total investments in Pfizer (PFE), as well as 3.9% in Merck (MRK), 3.9% in Eli Lilly (LLY), and 7.8% in Johnson & Johnson (JNJ).